Spyre Therapeutics (SYRE) Other Operating Expenses (2023 - 2026)
Spyre Therapeutics (SYRE) reported Other Operating Expenses of $30.0 million for Q1 2026, up 200.0% quarter-over-quarter from $10.0 million in Q2 2025.
Spyre Therapeutics (SYRE) Other Operating Expenses (2023 - 2026) Analysis & Trends
Spyre Therapeutics has reported Other Operating Expenses for 3 years, with the latest figure at $30.0 million in Q1 2026.
- For the quarter ending Q1 2026, Other Operating Expenses changed N/A year-over-year to $30.0 million; the trailing twelve-month figure through Mar 2026 stood at $40.0 million (changed N/A YoY), and the FY2025 full-year result was $10.0 million, changed N/A from the prior year.
- Other Operating Expenses for Q1 2026 stood at $30.0 million, up from $10.0 million in the prior quarter.
- The five-year high for Other Operating Expenses was $130.5 million in Q2 2023, with the low at $1.8 million in Q4 2023.
- Historically, Other Operating Expenses has averaged $37.4 million across 3 years, with a median of $14.6 million in 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Spyre Therapeutics | 6.35 Bn | 6.35 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.00 Mn |
| Jun 30, 2025 | 10.00 Mn |
| Dec 31, 2023 | 1.84 Mn |
| Sep 30, 2023 | 14.61 Mn |
| Jun 30, 2023 | 130.49 Mn |